Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448125 | 1.00 | GPR119 (0.61) | GPR119MAP4K4HDAC1CHRM5CHRM1 | |
| SCHEMBL12740848 | 1.00 | GPR119 (0.61) | GPR119MAP4K4HDAC1CHRM5CHRM1 | |
| SCHEMBL23560775 | 0.89 | GPR119 (0.62) | GPR119MAP4K4HDAC1SETD7GRM1 | |
| SCHEMBL1448170 | 0.89 | GPR119 (0.65) | GPR119MAP4K4HDAC1SETD7GRM1 | |
| SCHEMBL1448169 | 0.89 | GPR119 (0.65) | GPR119MAP4K4HDAC1SETD7GRM1 | |
| SCHEMBL12740835 | 0.89 | GPR119 (0.65) | GPR119MAP4K4HDAC1SETD7GRM1 | |
| SCHEMBL23560705 | 0.88 | GPR119 (0.61) | GPR119MAP4K4HDAC1CHRM1GRM1 | |
| SCHEMBL20158931 | 0.88 | GPR119 (0.61) | GPR119MAP4K4HDAC1CHRM1GRM1 | |
| SCHEMBL23560974 | 0.88 | GPR119 (0.61) | GPR119MAP4K4HDAC1SETD7GRM1 | |
| SCHEMBL20913420 | 0.87 | GPR119 (0.60) | GPR119MAP4K4HDAC1SETD7GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273238-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-9879016-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | GPR119 750/4885MAP4K4 204/4885HDAC1 1986/4885 |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | GPR119 750/4885MAP4K4 204/4885HDAC1 1986/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885MAP4K4 170/4885HDAC1 1884/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885MAP4K4 170/4885HDAC1 1884/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | GPR119 1393/4885MAP4K4 335/4885HDAC1 967/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | GPR119 976/4885MAP4K4 170/4885HDAC1 1884/4885 |
| US-10273238-B2 | Indazolones as modulators of TNF signaling | TNF, TNFRSF9, TNFRSF1A | GPR119 750/4885MAP4K4 204/4885HDAC1 1986/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | GPR119 1393/4885MAP4K4 335/4885HDAC1 967/4885 |
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | GPR119 1/4885MAP4K4 2128/4885HDAC1 1236/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | GPR119 1393/4885MAP4K4 335/4885HDAC1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.